Main Street Group’s Novo Nordisk NVO Stock Holding History

Main Street Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-37	Closed	-$4.72K	–	909
2024 Q1	$4.72K	Hold	37	–	–	﹤0.01%	660
2023 Q4	$3.83K	Buy	+37	New	+$3.66K	﹤0.01%	1017

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Main Street Group's NVO Position: Q2 2024 in Review

Main Street Group sold out of Novo Nordisk (NVO) in Q2 2024, closing a stake of 37 shares — an estimated $4.72K sold.

Main Street Group first reported a position in NVO in Q4 2023 and held it in 2 quarters. The position peaked at $4.72K in Q1 2024. 1,860 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

Main Street Group reported no remaining Novo Nordisk position as of Q2 2024 after selling out during the quarter.
Main Street Group sold 37 Novo Nordisk shares in Q2 2024, an estimated $4.72K.
Main Street Group first reported a position in Novo Nordisk in Q4 2023 and held it in 2 quarters.
Main Street Group's Novo Nordisk position peaked at $4.72K in Q1 2024.
1,860 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Main Street Group's 13F filing for Q2 2024, filed 6 Aug 2024.